What is the financial performance of Eli Lilly and Company for the period ending September 30, 2006?

For the third quarter of 2006, Eli Lilly and Company reported a 7% increase in net sales to $3.86 billion and a 10% increase in net income to $873.6 million, or $0.80 per diluted share. For the first nine months of 2006, net sales grew by 6% to $11.45 billion, and net income more than doubled to $2.53 billion, or $2.33 per diluted share, compared to the same period in 2005. This strong performance was driven by increased sales across key products and improved gross margins.

What are the major growth drivers for Eli Lilly's sales?

The primary drivers for sales growth in the third quarter and first nine months of 2006 included strong demand for Cymbalta, Byetta, Forteo, Alimta, and Zyprexa. Specifically, Cymbalta showed significant year-over-year growth, and diabetes care products like Humalog and Byetta also contributed positively. Sales in the U.S. and internationally both saw growth, supported by increased demand and, in some cases, favorable pricing and exchange rates.

What are the significant legal and regulatory matters impacting the company?

Eli Lilly is involved in several significant legal and regulatory matters. These include ongoing patent litigation concerning generic versions of its key drugs like Zyprexa, Evista, and Gemzar, where the company is defending its patent rights. Additionally, the company is facing numerous product liability lawsuits related to Zyprexa, alleging injuries such as diabetes and high blood-glucose levels. There are also ongoing civil investigations by U.S. Attorney's offices regarding marketing and promotional practices. While the company has settled a large number of Zyprexa claims, substantial litigation remains, and the outcomes could materially impact financial results.

What is the strategic significance of the ICOS Corporation acquisition?

Eli Lilly announced its agreement to acquire ICOS Corporation for approximately $2.1 billion in cash. This acquisition is strategically significant as it brings the full value of Cialis under Lilly's control, enabling operational efficiencies in its development, marketing, and sales. The company expects this acquisition to enhance its earnings and earnings growth rate starting in 2008, with a modest acceleration in sales growth thereafter. The transaction is subject to customary closing conditions.

LLY 10-Q Quarterly Report Q3 FY2006 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company (LLY) reported solid financial results for the third quarter and first nine months of 2006, showcasing robust sales growth and improved profitability. Net sales increased by 7% in the third quarter and 6% year-to-date, driven by strong performances in key therapeutic areas such as neurosciences and endocrinology, with notable contributions from products like Cymbalta, Byetta, Forteo, Alimta, and Zyprexa. The company demonstrated improved operational efficiency, with gross margins expanding year-over-year. This positive financial trajectory was achieved despite ongoing legal and regulatory challenges, including patent litigation and product liability claims, particularly concerning Zyprexa. A significant development during the period was the announcement of Eli Lilly's agreement to acquire ICOS Corporation for approximately $2.1 billion, a strategic move aimed at consolidating the value of Cialis and realizing operational efficiencies. This acquisition, expected to close in late 2006 or early 2007, is anticipated to enhance future earnings growth and accelerate sales. The company also made progress in its product pipeline with positive developments for Arxxant, Byetta, and Symbyax, underscoring its commitment to innovation and expanding its therapeutic offerings.

Key Highlights

1Net sales increased by 7% to $3.86 billion in Q3 2006 and by 6% year-to-date to $11.45 billion, indicating strong revenue growth.
2Net income for Q3 2006 rose by 10% to $873.6 million ($0.80 EPS), and year-to-date net income was $2.53 billion ($2.33 EPS), a significant increase compared to $1.28 billion ($1.17 EPS) in the prior year, boosted by increased sales and absence of a large prior year charge.
3The company announced the acquisition of ICOS Corporation for $2.1 billion, a strategic move to fully control Cialis and realize synergies, expected to impact earnings positively from 2008.
4Key products like Cymbalta, Byetta, Forteo, and Alimta showed substantial sales growth, contributing significantly to the overall revenue increase.
5Gross margins improved to 77.7% in Q3 2006, up from 76.5% in Q3 2005, reflecting improved operational efficiencies and pricing.
6Research and development expenses remained a significant investment, representing 20% of sales for both the quarter and the nine-month period, underscoring the company's commitment to innovation.
7The company is actively managing significant legal proceedings, including patent litigation for Zyprexa, Evista, and Gemzar, and ongoing Zyprexa product liability claims, for which a substantial charge was recognized in 2005.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2006

Summary

Key Highlights

Frequently Asked Questions